Proteins.1 Raises $4.7M Pre-seed To Advance Diagnostics Technology

The round was led by Lifeline Ventures and Cloudberry Ventures, with participation from VTT and Business Finland.

Founded on technology from the VTT Technical Research Centre of Finland and led by CEO Prateek Singh, the company is developing a patented single-molecule protein amplification platform for ultra-sensitive disease detection.

Proteins.1 aims to overcome a long-standing limitation in diagnostics: unlike DNA, proteins cannot be amplified, despite often being the earliest indicators of disease.

Read Also - Zynt Raises $500K Pre-Seed To Build AI-Powered B2B Sales Intelligence Platform

The company addresses this gap with a physics-based approach using magnets and semiconductor photonics to enable highly sensitive detection of proteins and nucleic acids from very small samples.

The funding will support expansion and further development of its technology, with the long-term goal of enabling earlier disease detection at the molecular level, before symptoms appear.

About Proteins.1

Proteins.1 is developing a physics-based, enzyme-free multiomics platform that enables single-molecule analysis to improve detection and understanding of health and biological processes.